- Home
- CVKD vs MTVA Comparison
CVKD vs MTVA Comparison
Compare CVKD & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- MTVA
- Stock Information
- Founded
- CVKD 2022
- MTVA 2014
- Country
- CVKD United States
- MTVA United States
- Employees
- CVKD N/A
- MTVA N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- MTVA
- Sector
- CVKD Health Care
- MTVA
- Exchange
- CVKD Nasdaq
- MTVA NYSE
- Market Cap
- CVKD 20.8M
- MTVA 18.9M
- IPO Year
- CVKD 2023
- MTVA N/A
- Fundamental
- Price
- CVKD $16.17
- MTVA $1.60
- Analyst Decision
- CVKD Strong Buy
- MTVA
- Analyst Count
- CVKD 2
- MTVA 0
- Target Price
- CVKD $46.00
- MTVA N/A
- AVG Volume (30 Days)
- CVKD 79.1K
- MTVA 279.5K
- Earning Date
- CVKD 11-07-2024
- MTVA 11-07-2024
- Dividend Yield
- CVKD N/A
- MTVA N/A
- EPS Growth
- CVKD N/A
- MTVA N/A
- EPS
- CVKD N/A
- MTVA N/A
- Revenue
- CVKD N/A
- MTVA N/A
- Revenue This Year
- CVKD N/A
- MTVA N/A
- Revenue Next Year
- CVKD N/A
- MTVA N/A
- P/E Ratio
- CVKD N/A
- MTVA N/A
- Revenue Growth
- CVKD N/A
- MTVA N/A
- 52 Week Low
- CVKD $5.40
- MTVA $1.55
- 52 Week High
- CVKD $32.55
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- CVKD 61.78
- MTVA N/A
- Support Level
- CVKD $10.65
- MTVA N/A
- Resistance Level
- CVKD $12.25
- MTVA N/A
- Average True Range (ATR)
- CVKD 1.68
- MTVA 0.00
- MACD
- CVKD 0.32
- MTVA 0.00
- Stochastic Oscillator
- CVKD 76.54
- MTVA 0.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.